AstraZeneca (NASDAQ:AZN) said Monday its marketing authorization application for its investigational COVID-19 prevention drug, sipavibart, has been accepted for an accelerated assessment by the EU drug regulator. The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use granted sipavibart accelerated assessment as it was deemed of major interestContinue Reading
Alnylam Pharmaceuticals (NASDAQ:ALNY) was the best performing large cap ($30B+) pharma or biotech in Q2, returning ~58.5% in the period. The biotech’s strong performance was helped significantly in late June when it reported strong pivotal trial results for vutrisiran, a treatment for ATTR amyloidosis with cardiomyopathy, sending shares skyrocketing. FollowingContinue Reading
jetcityimage/iStock Editorial via Getty Images AstraZeneca (NASDAQ:AZN) announced Tuesday that its blockbuster immunotherapy Imfinzi failed in a late-stage trial for patients with early-stage non-small cell lung cancer whose tumors have been surgically removed. Citing data from a Phase 3 trial called ADJUVANT BR.31, the company said Imfinzi did not demonstrateContinue Reading
Roland Magnusson/iStock Editorial via Getty Images BenevolentAI (OTC:BAIVF) Tuesday said that AstraZeneca (NASDAQ:AZN) has added a novel target for systemic lupus erythematosus to its discovery portfolio through its collaboration with the company. This is the second target to be selected this year from the extended collaboration with AstraZeneca (AZN), highlightingContinue Reading
